Atlanta VAHCS named one of 18 VA sites to test efficacy of GLP-1 as treatment for alcohol use disorder

Atlanta VAHCS today announced its participation in a new clinical trial to evaluate the efficacy of semaglutide, a GLP-1 receptor agonist used to treat diabetes, as treatment for alcohol use disorder (AUD).

Currently, more than 400,000 Veterans nationwide are diagnosed with AUD, and current data estimates that AUD affects nearly 11% of U.S. adults.

“AUD affects many Veterans in our community, and we are proud to support research that seeks better treatments,” said Kai Mentzer director of Atlanta VA Health Care System. “By contributing to research that explores new treatment options for AUD, we are helping drive innovations that could improve the health and lives of the Veterans we serve and civilian populations outside of VA.”

 Semaglutide has drawn scientific interest because it may affect the parts of the brain involved in how the body experiences rewards. An analysis published in March found that patients receiving GLP‑1 medications experience lower rates of AUD and substance use disorders compared with similar patients taking other diabetes medications. Among individuals with existing SUDs, GLP‑1 medications have been associated with fewer emergency visits, hospitalizations, and other adverse outcomes. These findings highlight the need for a controlled clinical trial to determine whether a GLP-1, such as semaglutide, can reduce alcohol use among Veterans.

The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans trial, will enroll more than 600 Veterans. Participants between the ages of 18 and 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo over a 24‑week period, followed by a safety follow‑up. Researchers will track changes in drinking, health, and quality of life to determine whether the medication offers a meaningful new treatment option.

Recruitment begins on Oct 19, 2026. For more information about participation, Veterans can contact their local VA medical center or visit ClinicalTrials.gov and search for the CRAVE trial.

VA strongly discourages self‑medicating or attempting to replace other AUD treatment options with GLP-1 medications or any other unprescribed substances. Evidence-based, proven treatments are available at VA facilities to support Veterans with AUD. Veterans should always consult their health care providers before making any treatment decisions.  

For more information, contact Chanel Cook at Chanel.Cook@va.gov or .

###